H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 187 Citations 137,127 1,262 World Ranking 94 National Ranking 68

Research.com Recognitions

Awards & Achievements

2012 - Warren Alpert Foundation Prize For the discovery, preclinical and clinical development of bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Gene
  • Cancer

Paul G. Richardson spends much of his time researching Multiple myeloma, Internal medicine, Bortezomib, Cancer research and Surgery. His work carried out in the field of Multiple myeloma brings together such families of science as Pharmacology and Dexamethasone. His Internal medicine research incorporates elements of Gastroenterology and Oncology.

The Bortezomib study which covers Proteasome inhibitor that intersects with Angiogenesis. The study incorporates disciplines such as Cell culture, Apoptosis, Protein kinase B, Cell growth and Bone marrow in addition to Cancer research. His studies in Surgery integrate themes in fields like Ixazomib and Hazard ratio.

His most cited work include:

  • Initial sequencing and analysis of the human genome. (18816 citations)
  • A phase 2 study of bortezomib in relapsed, refractory myeloma. (2325 citations)
  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (2128 citations)

What are the main themes of his work throughout his whole career to date?

His primary scientific interests are in Internal medicine, Multiple myeloma, Bortezomib, Oncology and Lenalidomide. His Internal medicine research includes elements of Gastroenterology and Surgery. His Multiple myeloma research incorporates themes from Cancer research and Dexamethasone.

His Bortezomib course of study focuses on Pharmacology and In vivo. His Oncology research is multidisciplinary, incorporating elements of Relapsed refractory, Clinical trial, Refractory Multiple Myeloma and Daratumumab. His Lenalidomide study combines topics in areas such as Regimen, Tolerability and Maintenance therapy.

He most often published in these fields:

  • Internal medicine (49.35%)
  • Multiple myeloma (47.24%)
  • Bortezomib (31.29%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (49.35%)
  • Multiple myeloma (47.24%)
  • Oncology (23.65%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Defibrotide. His study focuses on the intersection of Multiple myeloma and fields such as Cancer research with connections in the field of Immune system.

His Dexamethasone research is multidisciplinary, incorporating perspectives in Clinical endpoint, Refractory and Subgroup analysis. He has researched Lenalidomide in several fields, including Maintenance therapy, Progression-free survival, Neutropenia and Hazard ratio. His biological study spans a wide range of topics, including Proteasome inhibitor, Proteasome and Phases of clinical research.

Between 2017 and 2021, his most popular works were:

  • Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. (191 citations)
  • Oral selinexor-dexamethasone for triple-class refractory multiple myeloma (149 citations)
  • CD38 antibodies in multiple myeloma: back to the future. (147 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Gene
  • Cancer

Paul G. Richardson mainly investigates Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide. His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology. As part of his studies on Multiple myeloma, Paul G. Richardson frequently links adjacent subjects like Progression-free survival.

His research integrates issues of Clinical trial, Refractory, Stem cell, Disease and Monoclonal antibody in his study of Oncology. His Dexamethasone research includes themes of Relapsed refractory, Clinical endpoint and Cancer research. His study looks at the relationship between Bortezomib and fields such as Proteasome inhibitor, as well as how they intersect with chemical problems.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

Initial sequencing and analysis of the human genome.

Eric S. Lander;Lauren M. Linton;Bruce Birren;Chad Nusbaum.
Nature (2001)

25862 Citations

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Paul G. Richardson;Bart Barlogie;James Berenson;Seema Singhal.
The New England Journal of Medicine (2003)

3226 Citations

International uniform response criteria for multiple myeloma

B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
Leukemia (2006)

2975 Citations

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)

2881 Citations

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)

2665 Citations

Community structure and metabolism through reconstruction of microbial genomes from the environment

Gene W. Tyson;Jarrod Chapman;Jarrod Chapman;Philip Hugenholtz;Eric E. Allen.
Nature (2004)

2485 Citations

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake E. Delmore;Ghayas C. Issa;Madeleine E. Lemieux;Peter B. Rahl.
Cell (2011)

2411 Citations

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos.
The New England Journal of Medicine (2008)

2229 Citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima;Paul Richardson;Dharminder Chauhan;Vito J. Palombella.
Cancer Research (2001)

2229 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Paul G. Richardson

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 399

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 347

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 344

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 302

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 293

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 283

Nikhil C. Munshi

Nikhil C. Munshi

Harvard University

Publications: 277

Antonio Palumbo

Antonio Palumbo

University of Turin

Publications: 247

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 243

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 241

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 238

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 217

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 214

Ola Landgren

Ola Landgren

University of Miami

Publications: 204

Pieter Sonneveld

Pieter Sonneveld

Erasmus University Rotterdam

Publications: 198

Something went wrong. Please try again later.